CREM Activators
The class of CREM activators comprises a diverse range of chemicals that modulate the activity of the cAMP/PKA/CREB/CREM signaling pathway. Forskolin and rolipram act as direct activators by elevating cAMP levels, leading to PKA activation and subsequent phosphorylation of CREB and CREM. Synthetic analogs like 8-Bromo-cAMP and dibutyryl cAMP directly stimulate PKA, promoting CREM-mediated gene expression. In addition, chemicals like 4α-Phorbol 12,13-didecanoate and A23187 activate CREM through alternative pathways involving PKC and calcium-dependent mechanisms, respectively. Resveratrol, through SIRT1 modulation, and H89, a PKA inhibitor, represent indirect activators by influencing the phosphorylation status of CREB.
Furthermore, inhibitors of specific pathways such as PD98059, SP600125, Wortmannin, and GW5074 indirectly activate CREM by suppressing the MAPK, JNK, PI3K, and Raf/MEK/ERK pathways, respectively. These chemicals alter the phosphorylation status of CREB, contributing to CREM activation and subsequent gene expression. Collectively, CREM activators play a crucial role in modulating the cAMP/PKA/CREB/CREM pathway, illustrating the intricate regulatory network governing CREM activation. These chemicals can serve as valuable tools in understanding and manipulating the transcriptional processes controlled by CREM, shedding light on applications in various cellular and research contexts.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates CREM by stimulating adenylate cyclase, leading to increased cAMP levels. Elevated cAMP activates protein kinase A (PKA), which in turn phosphorylates CREB, leading to CREM activation and gene expression. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram, a phosphodiesterase (PDE) inhibitor, increases cAMP levels by preventing its degradation. Elevated cAMP activates PKA, resulting in CREM activation through phosphorylation of CREB and subsequent gene expression. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-Bromo-cAMP is a synthetic analog of cAMP that directly activates PKA, leading to phosphorylation of CREB and subsequent activation of CREM. This chemical serves as a direct activator of the cAMP/PKA/CREB/CREM pathway. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Dibutyryl cAMP is a cell-permeable derivative of cAMP that activates PKA and, consequently, CREM. This chemical serves as a direct activator of the cAMP/PKA/CREB/CREM pathway, promoting CREM-mediated gene expression. | ||||||
4α-Phorbol 12,13-didecanoate | 27536-56-7 | sc-201210 sc-201210A | 1 mg 5 mg | $188.00 $676.00 | 3 | |
4α-Phorbol 12,13-didecanoate activates CREM by stimulating protein kinase C (PKC), leading to the phosphorylation of CREB and subsequent CREM activation. This chemical acts as an activator of the PKC/CREB/CREM signaling pathway. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187, a calcium ionophore, activates CREM through a calcium-dependent mechanism. Increased intracellular calcium levels activate calmodulin-dependent protein kinase (CaMK), leading to CREB phosphorylation and subsequent CREM activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, a MEK inhibitor, indirectly activates CREM by inhibiting the mitogen-activated protein kinase (MAPK) pathway. Suppression of the MAPK pathway results in reduced phosphorylation of CREB, leading to CREM activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, indirectly activates CREM by inhibiting the c-Jun N-terminal kinase (JNK) pathway. Suppression of JNK reduces phosphorylation of c-Jun, leading to decreased inhibition of CREB and subsequent CREM activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3K inhibitor, indirectly activates CREM by inhibiting the phosphoinositide 3-kinase (PI3K) pathway. Suppression of PI3K leads to decreased Akt activation, resulting in reduced phosphorylation of CREB and CREM activation. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074, a c-Raf inhibitor, indirectly activates CREM by inhibiting the Raf/MEK/ERK pathway. Suppression of this pathway reduces phosphorylation of CREB, leading to CREM activation and subsequent gene expression. | ||||||